Healaflow

PreclinicalBiologic

TTianjin Medical University Eye Hospital

Healaflow is one of 5 biologic programs targeting Rhegmatogenous Retinal Detachment. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Rhegmatogenous Retinal DetachmentActive, not recruiting

Rhegmatogenous Retinal DetachmentPreclinical

Active, not recruiting

Competition

Competitive Landscape

5 competitors in Rhegmatogenous Retinal Detachment

#DrugCompanyPhaseTrials

Actigall

Lovenox

1 3

Intravitreal Topotecan

UUnity Health Toronto

Phase 2

1 4

Sulfur Hexafluoride

TTurku University Hospital

Preclinical

1 5

Healaflow

TTianjin Medical University Eye Hospital

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Rhegmatogenous Retinal Detachment1 trial

Healaflow Patch for the Treatment of Rhegmatogenous Retinal Detachment

Completed·TTianjin Medical University Eye Hospital·N/A·NCT03542162·37 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Healaflow. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Healaflow compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Healaflow. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Tianjin Medical University Eye Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Preclinical[1]
Company: TTianjin Medical University Eye Hospital

Healaflow

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Rhegmatogenous Retinal Detachment1 trial

References

Drug Info

Quick Facts

Related News